Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT03790072 Completed - Clinical trials for Acute Myeloid Leukemia

Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)

Start date: November 27, 2018
Phase: Phase 1
Study type: Interventional

This study investigates the potential curative properties of gamma delta T-cells obtained from a blood-related donor of an AML patient.

NCT ID: NCT03789981 Recruiting - Clinical trials for Acute Myeloid Leukemia

Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia

Immune-AML
Start date: July 19, 2019
Phase:
Study type: Observational

This is a multicenter, prospective, translational study, to evaluate the immunogenic profile of AML cases according to immune checkpoint molecule expression.

NCT ID: NCT03788291 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Start date: March 25, 2019
Phase: Phase 2
Study type: Interventional

The main purpose of this research study is to find out if the combination of acalabrutinib and high frequency low dose subcutaneous rituximab is safe and effective in patients who have previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

NCT ID: NCT03787498 Completed - Clinical trials for High-risk Myelodysplastic Syndrome (MDS)

A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Start date: March 19, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

NCT ID: NCT03779854 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Start date: August 29, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.

NCT ID: NCT03772925 Active, not recruiting - Clinical trials for Refractory Acute Myeloid Leukemia

Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Start date: June 20, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies side effects and best dose of pevonedistat and belinostat in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has come back (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as pevonedistat and belinostat, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT03771157 Completed - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

Start date: February 1, 2019
Phase: Early Phase 1
Study type: Interventional

The primary objective of the study is to assess the capability of a patient with Chronic Lymphocytic Leukemia (CLL) or Waldenström Macroglobulinemia (WM) to generate an immune response to the Shingrix vaccine under first-line BTK inhibitors.

NCT ID: NCT03770429 Recruiting - Leukemia Clinical Trials

AZD6738 for Patients With Progressive MDS or CMML

Start date: August 5, 2019
Phase: Phase 1
Study type: Interventional

This research study is studying a research drug called AZD6738 as a possible treatment for Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia .

NCT ID: NCT03766763 Recruiting - Clinical trials for Chronic Lymphoid Leukemia

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

Start date: May 22, 2019
Phase: Phase 2
Study type: Interventional

Open label, single arm, multicenter phase II trial.

NCT ID: NCT03766126 Recruiting - Clinical trials for Acute Myeloid Leukemia, in Relapse

Lentivirally Redirected CD123 Autologous T Cells in AML

Start date: December 6, 2018
Phase: Phase 1
Study type: Interventional

Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in Acute Myeloid Leukemia (AML) subjects.